139P The timing, dynamics, and co-occurrence of immune-related adverse events with a PD-L1 inhibitor in non-small cell lung cancer. (December 2022) - Smith, K.E.; Pritzl, S.; Yu, W.; Bara, I.; Thanarajasingam, G.; Kaul, M.; Williams, K.A.; Dueck, A.; Mansfield, A.S.